A dvances in treatment have resulted in declining mortality rates after acute myocardial infarction (MI). Unfortunately, the decrease in postinfarct mortality is paralleled by an increase in the incidence of heart failure in patients surviving with significant residual myocardial damage. 1 Loss of contractile tissue after MI induces profound alterations of left ventricular (LV) tissue architecture that are characterized by chamber dilatation and pathological hypertrophy of the noninfarcted myocardium, leading to contractile dysfunction and reduced long-term survival. 2 
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During midgestational heart development, the heart undergoes a dramatic increase in size that is attributable to cardiomyoblast proliferation and the concurrent formation of the coronary vascular system. 3, 4 LV contractile function increases during this period of rapid cardiac growth, 5 thus providing an example that cardiac mass and size can increase considerably without deleterious effects on systolic function or lifespan. Fibroblast growth factor (FGF) 9 acts as an essential inducer of midgestational cardiac growth and vascularization. 6, 7 FGF9 is a member of the FGF gene family, which comprises 22 functionally diverse polypeptides in humans and mice that can be divided into subfamilies based on their chromosomal location and evolutionary relationships, their function as intracellular or secreted proteins, and their biochemical properties. 8 FGF9 acts as a secreted factor and exerts its functions via transmembrane FGF receptors on target cells. 8, 9 Because of its affinity for pericellular heparan sulfate proteoglycans, FGF9 diffuses locally within tissues and acts primarily in a paracrine fashion. 10 During midgestation, FGF9 is expressed by the epicardium and endocardium and provides an epithelial-to-mesenchymal signal to stimulate coronary artery formation and cardiomyoblast expansion in the developing myocardium. 6, 7 FGF9 is expressed only at low levels in the adult heart, 11 and previous transcriptome analyses provided no evidence for a reinduction of FGF9 expression after MI. 12 We have recently shown that FGF9 is secreted from bone marrow cells (BMCs) that we have found in a randomized controlled cell therapy trial to enhance the recovery of LV ejection fraction in patients after MI. 13, 14 Paracrine mechanisms are thought to contribute to the beneficial effects of BMCs on perfusion and function of the infarcted heart that have been demonstrated in experimental studies and some clinical trials. 15, 16 Considering the pivotal role of FGF9 in supporting cardiac growth and vascularization during development, we therefore hypothesized that increased expression levels of FGF9 may help the heart adapt to a MI. Our data indicate that conditional transgenic expression of FGF9 in the adult mouse myocardium promotes adaptive LV hypertrophy with enhanced systolic function and reduced heart failure mortality after MI, thus pointing to FGF9 as a potential therapeutic strategy after MI.
Methods
An expanded Methods section is provided in the online-only Data Supplement.
Mouse and rat cells were stimulated with recombinant mouse FGF9 and bone morphogenetic protein 6 (BMP6), human cells with recombinant human FGF9. Dorsomorphin was used as an inhibitor of activin receptor-like kinase (ALK) 2, ALK3, and ALK6. 17 SB-431542 was used as an inhibitor of ALK4, ALK5, and ALK7. 18 A tetracycline-responsive transgene system 19 was used to allow temporally regulated expression of FGF9 in adult cardiac myocytes. Mouse FGF9 cDNA was placed under the chimeric tetracyclineresponsive ␣-myosin heavy chain (MHC) promoter (responder mice). FGF9 transgenic mice were crossed with transgenic mice expressing the tetracycline transactivator (tTA) under the control of the constitutive ␣MHC promoter. All mice were generated and bred on an FVB/N background. Doxycycline was provided in the drinking water from mating up to 8 weeks after birth to inhibit FGF9 transgene expression; doxycycline was then withdrawn to induce FGF9 expression.
MI was induced in male mice by permanent left anterior descending coronary artery (LAD) ligation during isoflurane anesthesia. A sham operation was performed in control mice. Mice were followed up and inspected daily from 24 hours up to 6 weeks after MI. Autopsies were performed on all dead animals; rupture was diagnosed by the presence of a blood clot around the heart and in the chest cavity; heart failure was diagnosed by chest fluid accumulation. 20, 21 Replication-deficient adenoviruses encoding mouse FGF9 (Ad.FGF9) or ␤-galactosidase (Ad.lacZ) were injected into the LV cavity immediately after LAD ligation.
Steady-state LV pressure-volume loops were recorded with a 1.4F micromanometer conductance catheter (SPR-839, Millar Instruments, Houston, TX) inserted via the right carotid artery during isoflurane anesthesia. Transthoracic echocardiography was performed with a linear 30-MHz transducer in mice sedated with isoflurane.
Infarct sizes were determined in paraffin-embedded tissue sections stained with Masson trichrome. Infarct sizes were calculated as the average ratio of endocardial scar length to endocardial total LV circumference in basal, midventricular, and apical sections. Scar thickness was measured at the center of the infarct in the same sections. Midventricular cryosections were prepared for fluorescent (immuno)staining. Cardiomyocytes were outlined by TRITCconjugated wheat germ agglutinin (WGA). The circumferences of 40 to 50 myocytes were traced and digitized to calculate mean cardiomyocyte cross-sectional area. Ki67 was detected with a rabbit polyclonal antibody; troponin T, with a mouse monoclonal antibody. Capillaries were stained with fluorescein-labeled GSL I-isolectin B4. Conductance vessels were identified by their diameter (Ͼ20 m) after immunostaining for smooth muscle ␣-smooth muscle actin (␣SMA). Interstitial collagen content was determined by Picrosirius Red polarization microscopy.
Cardiac gene expression levels were quantified by quantitative polymerase chain reaction (polymerase chain reaction primers are shown in Table I in the online-only Data Supplement).
Human coronary artery endothelial cells (HCAECs) were purchased from Provitro (Berlin, Germany). Primary mouse heart endothelial cells were isolated as previously described. 22 Endothelial cell proliferation was measured by bromodeoxyuridine incorporation. Network formation was assayed in tissue culture plates coated with growth factor-reduced Matrigel. Ventricular cardiomyocytes were isolated from 1-to 3-day-old Sprague-Dawley rats by Percoll density gradient centrifugation. Cell size was determined by planimetry; protein content was assessed by the Bradford assay. Adult ventricular cardiomyocytes were isolated from 4-month-old Wistar rats. Cross-sectional area of adult cardiomyocytes was calculated as follows: (cell width/2) 2 ϫ. Net protein synthesis was measured by [ 14 C] phenylalanine incorporation.
Antibodies against mouse FGF9, BMP6, phospho-SMAD1/5, phospho-SMAD3, and ␤-actin were used for immunoblotting. Expression levels of 174 secreted factors were assessed in conditioned HCAEC supernatants with Human Cytokine ProteinChip Array C Series 2000 membranes (Ray Biotech, Norcross, GA).
Statistical Analysis
Data are presented as meanϮSEM. The unpaired t test was used for comparisons between 2 groups. For comparisons between Ͼ2 groups, we used 1-way ANOVA if there was 1 independent variable and 2-way ANOVA if there were 2 independent variables (ie, genotype and LAD ligation status). The Tukey posthoc test was used to adjust for multiple comparisons. Pairwise comparisons were made between sham groups across genotypes, sham versus MI within each genotype, and MI groups across genotypes. Kaplan-Meier curves were created to illustrate cumulative mortality after MI, and statistical assessment was performed by the log-rank test. A 2-tailed value of PϽ0.05 was considered to indicate statistical significance. strategy ( Figure 1A ). Two independent responder transgenic lines were generated (lines 1 and 3). Each permitted expression of FGF9 in the heart only in the presence of the driver transgene encoding the tTA when doxycycline was absent. In all experiments, doxycycline was administered from mating up to 8 weeks after birth, which blocks developmental expression, followed by doxycycline withdrawal thereafter to permit transgene expression starting in young adulthood ( Figure 1B) . In tTA/FGF9 double transgenic (DTG) mice from line 1, LV FGF9 protein expression was increased 6.3-fold at 2 weeks and 4.8-fold at 8 weeks after doxycycline withdrawal compared with wild-type (WT) mice ( Figure 1C  and 1D) . A similar degree of FGF9 induction was observed in line 3 ( Figure 1C and 1D ). Data from line 1 are presented here. Line 3 displayed an identical cardiac phenotype (not shown).
FGF9 Promotes Cardiac Hypertrophy
To assess the effects of prolonged FGF9 expression on the adult unstressed myocardium, mice were followed up for up to 8 weeks after doxycycline withdrawal. Mice underwent a sham operation 2 weeks after doxycycline removal to allow comparison with mice undergoing LAD ligation at this time point (see below). No increase in LV mass was apparent at 2 weeks, but after 8 weeks of doxycycline withdrawal, LV mass ( Figure 2A ) and the ratio of LV mass to body mass ( Figure 2B ) were increased in DTG compared with WT and tTA control mice. No differences in body weight were observed between the genotypes (not shown). The increases in LV mass and heart size ( Figure 2C ) in DTG mice were related to an increase in LV wall thickness with no apparent increase in LV cavity diameter ( Figure 2D ). On histological examination, DTG mice displayed a significant increase in LV cardiomyocyte cross-sectional area 8 weeks after doxycycline withdrawal compared with WT and tTA controls ( Figure 2E and 2F) . Expression of transcripts of atrial natriuretic peptide, ␣MHC, ␤MHC, sarco(endo)plasmic reticulum Ca 2ϩ ATPase 2a (SERCA2a), and phospholamban was not significantly different between WT, tTA, and DTG mice (Table II in the online-only Data Supplement, sham).
No differences in tail-cuff blood pressure or heart rate were observed between the 3 genotypes after 8 weeks of doxycycline treatment or during 8 weeks after doxycycline withdrawal ( Figure I in the online-only Data Supplement, sham). Eight weeks after doxycycline withdrawal, invasive pressure-volume measurements revealed no significant differences between the 3 genotypes with regard to LV end-diastolic or end-systolic volumes and several indexes of systolic and diastolic function ( 
FGF9 Enhances Microvessel Density in the Myocardium
Two weeks after doxycycline withdrawal, the density of proliferating, Ki67 ϩ isolectin B4 ϩ endothelial cells was increased in the LV myocardium of DTG mice ( Figure 3A and 3B). Eight weeks after doxycycline withdrawal, Ki67 ϩ endothelial cell density remained elevated in DTG mice and was accompanied by an increase in capillary density ( Figure  3A and 3C) and an increase in the density of small (20 to 50 m in diameter) ␣SMA ϩ conductance vessels ( Figure 3A  and 3D ). Two and 8 weeks after doxycycline withdrawal, no Ki67 ϩ cardiomyocyte nuclei were detectable in multiple tissue sections stained with anti-Ki67 and anti-troponin T antibodies and DAPI (not shown).
Eight weeks after doxycycline withdrawal, no significant differences emerged between the genotypes (4 to 6 mice per group) in the density of larger (Ͼ50 m) ␣SMA ϩ vessels (WT, 0.38Ϯ0.13; tTA, 0.40Ϯ0.06; DTG, 0.33Ϯ0.05 vessels per 100 cardiomyocytes) and interstitial collagen volume fraction in the LV myocardium (WT, 0.17Ϯ0.01%; tTA, 0.16Ϯ0.01%; DTG, 0.17Ϯ0.01%).
FGF9 Stimulates Endothelial Cell Proliferation, Network Formation, and Release of Prohypertrophic Factor(s)
Cardiomyocyte hypertrophy and microvessel expansion represented the main phenotypes observed in FGF9-expressing DTG mice. To explore whether FGF9 has a direct effect on cardiomyocyte hypertrophy, we stimulated neonatal cardiomyocytes with increasing concentrations of FGF9. Only at high concentrations (Ն100 ng/mL) did FGF9 promote an increase in cardiomyocyte size, which was, however, much less pronounced than the response to endothelin 1 that we used as a positive control ( Figure 4A ). FGF9 did not promote a significant increase in cardiomyocyte protein content, which was chosen as an additional readout of hypertrophy ( Figure III in the online-only Data Supplement).
Although cardiomyocytes were only weakly responsive to FGF9, HCAECs responded to markedly lower concentrations (Յ10 ng/mL) of FGF9 with proliferation ( Figure  4B ) and network formation ( Figure 4C and 4D). The effects of FGF9 on HCAECs were at least as potent as the effects of vascular endothelial growth factor, which we used as positive control. Heart rate, bpm
LV end-systolic pressure, mm Hg
LV end-diastolic pressure, mm Hg 
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These data led us to hypothesize that FGF9 induces cardiomyocyte hypertrophy by stimulating endothelial cells to release prohypertrophic factor(s). Indeed, conditioned supernatants from HCAECs stimulated for 24 hours with 10 ng/mL FGF9 promoted a significant increase in cardiomyocyte size, whereas conditioned supernatants from unstimulated HCAECs did not ( Figure 4E and 4F). Similar results were obtained when protein content was used as a readout of hypertrophy ( Figure 4G ).
BMP6 Is Induced by FGF9 In Vitro and In Vivo and Stimulates Cardiomyocyte Hypertrophy
An antibody array detecting 174 cytokines, chemokines, and growth factors was used to identify factors secreted from HCAECs stimulated with 10 ng/mL FGF9 for 24 hours. Nine secreted factors were induced Ն2-fold by FGF9 in 2 independent array analyses (Table IV in the online-only Data Supplement). BMP6 was induced 2.5-fold and 6.8-fold in the 2 experiments, and its average increase was greater than for any other factor. 
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The effects of FGF9-stimulated HCAEC supernatants on neonatal cardiomyocyte size were reduced by 79% by a neutralizing anti-BMP6 antibody, indicating that BMP6 is responsible for a substantial part of the paracrine prohypertrophic effect ( Figure 5A ). Corroborating this finding, we found that recombinant BMP6 promoted a robust increase in cardiomyocyte size in concentrations as low as 1 ng/mL ( Figure 5A ). The effects of BMP6 on cardiomyocyte size were abolished by the ALK2/3/6 inhibitor dorsomorphin but not by the ALK4/5/7 inhibitor SB-431542 ( Figure 5A ). Similarly, BMP6 promoted an increase in cardiomyocyte protein content in an ALK2/3/6-dependent manner ( Figure Like neonatal cardiomyocytes, adult cardiomyocytes responded to BMP6, but not FGF9, with a significant hypertrophic response characterized by increases in cross-sectional area ( Figure 5C and 5D) and [ 14 C] phenylalanine incorporation ( Figure 5E ).
Eight weeks after doxycycline withdrawal, expression levels of BMP6 and phosphorylated SMAD1/5, but not phosphorylated SMAD3, were increased in the LVs of FGF9-expressing DTG mice, showing that FGF9 enhances the expression of BMP6 and activation of BMP6 downstream targets in vivo ( Figure 5F ).
LV Hypertrophy With Microvessel Expansion and Reduced Fibrosis After MI in FGF9-Expressing Mice
To explore the effects of transgenic FGF9 in the setting of MI, WT, tTA, and DTG mice underwent LAD ligation 2 weeks after doxycycline withdrawal and were followed up for an additional 6 weeks. Expression levels of endogenous FGF9 in the noninfarcted LV myocardium of WT mice did not change during this time period ( Figure 6A ). The ratio of scar length to endocardial circumference and scar thickness 
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were not significantly different between WT, tTA, and DTG mice ( Figure 6B and Table 2 ). DTG animals, however, developed more LV hypertrophy with greater LV mass and ratio of LV mass to body mass compared with WT and tTA mice ( Figure 6B and Table 2 ). Body weight was not significantly different between the genotypes (not shown). Enhanced LV hypertrophy in DTG mice was not related to differences in tail-cuff blood pressure or heart rate after MI ( Figure I in the online-only Data Supplement, LAD ligation). Postinfarct LV hypertrophy in DTG mice was characterized by a greater mean cardiomyocyte cross-sectional area, a higher density of Ki67 ϩ isolectin B4 ϩ endothelial cells, a greater capillary density, and an increased density of small (20 to 50 m in diameter) ␣SMA ϩ conductance vessels (Table 2) . DTG mice developed less interstitial fibrosis in the noninfarcted LV myocardium compared with WT and tTA mice ( Figure 6C and 6D). Induction of atrial natriuretic peptide and downregulation of ␣MHC and SERCA2a mRNA expression in the noninfarcted LV myocardium were attenuated in DTG mice (Table II in 
Improved Systolic Function and Reduced Heart Failure Mortality After MI in FGF9-Expressing Mice
As shown by invasive pressure-volume measurements, all 3 genotypes developed LV dilatation (increased LV end-diastolic volume, trend only in DTG mice) and systolic and diastolic dysfunction 6 weeks after MI ( Figure II in the online-only Data Supplement. Better systolic function in DTG mice after MI was confirmed by 2-dimensional echocardiography (Table III in the online-only Data Supplement, LAD ligation). Six weeks after MI, 14 of 39 WT mice (36%), 14 of 41 tTA mice (34%), and 5 of 35 DTG mice (14%) had died with signs of heart failure (Pϭ0.032; Figure 6E ). Heart failure deaths occurred between days 1 and 19 after LAD ligation. Rupture deaths were observed less frequently in our FVB/N mice and were not significantly affected by transgenic FGF9 (WT, 6 of 39, 15%; tTA, 5 of 41, 12%; DTG, 4 of 35, 11%; Pϭ0.78, Figure 6E ). To explore how transgenic FGF9 reduces early heart failure mortality, echocardiography and LV histology were also performed 1 week after MI. Already at this early time point, significant increases in LV capillary density, cardiomyocyte cross-sectional area, wall thickness, and frac- 
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tional area change were observed in DTG mice, strongly suggesting that LV hypertrophy with enhanced systolic function contributed to the reduction in heart failure mortality (Table V in the online-only Data Supplement).
FGF9 Gene Transfer Improves Systolic Function and Reduces Heart Failure Mortality After MI
To further explore the therapeutic potential of FGF9 after MI, WT mice were treated with a single injection of Ad.FGF9 or Ad.lacZ into the LV cavity immediately after LAD ligation (1ϫ10 8 plaque-forming units [pfu] per mouse). Seven days after adenoviral FGF9 gene transfer, FGF9 protein levels were increased in the noninfarcted LV and liver ( Figure 7A ). Increased FGF9 levels were detected in the noninfarcted LV as early as 3 days after gene transfer ( Figure 7B ). As shown by immunostaining 7 days after FGF9 gene transfer, FGF9 was expressed mostly in cardiomyocytes, with Ϸ30% to 35% of myocytes showing strong FGF9 expression (3 animals); an example is shown in Figure 7C .
Six weeks after LAD ligation, Ad.FGF9-treated mice displayed greater LV mass and ratio of LV mass to body mass ( Figure 7D ) and better systolic function with a smaller LV end-systolic area and greater LV fractional area change ( Figure 7E ) compared with Ad.lacZ-treated mice. Infarct sizes were not significantly different between the 2 groups (Ad.lacZ, 38Ϯ3%, nϭ6; Ad.FGF9, 37Ϯ4%, nϭ8).
Six weeks after MI, 10 of 30 Ad.lacZ-treated mice (33%) and 3 of 30 Ad.FGF9-treated mice (10%) had died with signs of heart failure (Pϭ0.032; Figure 7F ). Heart failure deaths occurred between days 1 and 18 after LAD ligation. Rupture deaths were observed less frequently and were not significantly affected by FGF9 (Ad.lacZ, 2 of 30, 7%; Ad.FGF9, 3 of 30, 10%; Pϭ0.70; Figure 7F ). Already 1 week after MI, significant increases in LV capillary density, cardiomyocyte cross-sectional area, wall thickness, and fractional area change were observed in Ad.FGF9-treated animals, suggesting again that FGF9-induced LV hypertrophy with enhanced systolic function contributed to the reduction in early heart failure mortality (Table VI in the online-only Data Supplement).
Discussion
In contrast to previous investigations in transgenic mice examining the function of FGF family members in the myocardium, 24 -27 the inducible strategy used here bypassed any developmental effects that might have occurred in embryos or neonates and enabled us to explore the effects of FGF9 specifically in the adult heart. In unstressed mice, FGF9 stimulated concentric LV hypertrophy with microvessel expansion without increases in interstitial fibrosis and with no changes in the expression levels of cardiac genes that are typically observed during pathological hypertrophy and heart failure. Systolic and diastolic function was preserved in FGF9-expressing mice. FGF9-induced cardiac hypertrophy therefore displayed structural, molecular, and functional characteristics of the adaptive hypertrophic response that is observed after physiological increases in cardiac workload. 28 -34 In the setting of MI, transgenic FGF9 similarly promoted microvessel expansion and enhanced cardiomyocyte hypertrophy in the noninfarcted LV myocardium. Infarct sizes and scar thickness were not affected by myocardial expression of FGF9. Enhanced interstitial fibrosis, increased expression levels of atrial natriuretic peptide, a shift in MHC isoform expression from ␣ to ␤, and decreased expression levels of SERCA2a are hallmarks of pathological hypertrophy, which develops in disease states with increased cardiac workload (eg, MI, valvular heart disease, hypertension) and may 
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ultimately lead to the development of heart failure. 33, 34 FGF9 antagonized these structural and molecular features of pathological hypertrophy. Notably, FGF9 enhanced systolic function and reduced heart failure mortality after MI, thus clearly establishing that expression of FGF9 in the adult mouse myocardium is beneficial during recovery from an acute MI. Although interstitial LV fibrosis was attenuated and LV expression of SERCA2a was slightly augmented in FGF9-transgenic mice after MI, these parameters were still markedly abnormal compared with sham-operated mice, and diastolic function was not significantly enhanced by transgenic FGF9 (trend only for improvement in dP/dtmin). Previous studies in animal models of pathological hypertrophy have shown that exercise training can promote extra LV hypertrophy with favorable changes in gene expression signatures and, as investigated in some reports, with improved systolic function. [35] [36] [37] Therefore, it has been proposed that stimulation of physiological hypertrophy, either by moderate exercise or by activation of signaling pathways promoting physiological hypertrophy, may be applied therapeutically in disease states, leading to pathological hypertrophy and heart failure. 29, 38 Our study supports this emerging concept and provides the first evidence that a genetic intervention promoting a physiological-like increase in cardiac mass can lead to a marked reduction in heart failure mortality after MI. Consistent with previous reports, 20, 21 fatal infarct ruptures were observed less frequently in our FVB/N mice and were not significantly influenced by myocardial expression of FGF9 in our study.
On a histological level, microvessel expansion and cardiomyocyte hypertrophy represented the main phenotypes of FGF9 transgenic mice, and our data indicate that they may be interrelated. Coordinated growth of the coronary microvasculature is important to ensure adequate tissue perfusion and to maintain contractile function as the myocyte compartment expands during cardiac development 3, 4, 39 or exercise-induced physiological hypertrophy. 30 -32 Conversely, vascular rarefaction contributes to the decline in contractile function during chronic pressure overload-induced pathological hypertrophy. 40, 41 An increase in Ki67 ϩ endothelial cells was the first phenotype observed after FGF9 induction in the myocardium, consistent with an initial stimulatory effect of cardiomyocytederived transgenic FGF9 on endothelial cell proliferation. In accord with this hypothesis, FGF9 stimulated angiogenesis in several bona fide angiogenesis assays in vitro (shown for both HCAECs and mouse cardiac endothelial cells) but did not promote considerable cardiomyocyte hypertrophy, as shown in neonatal and adult rat cardiomyocytes.
In the hypertrophied heart, proangiogenic cytokines are released from cardiomyocytes and signal to adjacent capillaries to stimulate myocardial angiogenesis. 40, 41 Conversely, enhanced myocardial angiogenesis per se can induce cardiomyocyte hypertrophy in the absence of external stimuli, thus suggesting the existence of reciprocal, endothelial cellderived prohypertrophic signals. 42, 43 Conditioned supernatants from FGF9-stimulated endothelial cells (HCAECs or mouse cardiac endothelial cells) stimulated cardiomyocyte hypertrophy, which was mediated in part by paracrine release of the transforming growth factor-␤ cytokine family member BMP6. We found BMP6 to signal via BMP type I receptors ALK2/3/6, to activate SMAD 1/5, and to induce hypertrophy in neonatal and adult cardiomyocytes. BMP6 expression and SMAD1/5 phosphorylation were increased in the myocardium of FGF9 transgenic mice, confirming that FGF9 stimulates BMP6 signaling also in vivo. Of the many potential secondary paracrine effects induced by transgenic FGF9 in the myocardium, BMP6 therefore represents one potential mechanism whereby FGF9 promotes cardiomyocyte hypertrophy. We acknowledge the general limitations of using cell culture systems to provide mechanistic insight into in vivo phenotypes.
We have previously shown that intracoronary infusion of autologous BMCs enhances the recovery of systolic function in postinfarct patients, 13, 44 and we have identified FGF9 as a factor that is secreted from these cells. 14 Given the results of the present study, FGF9-mediated paracrine effects in the border zone of the infarct may contribute to the improvements in microvascular perfusion and regional contractility that have been observed after intracoronary BMC transfer in some clinical trials. 13, 16, 45, 46 Because FGF9 is 1 of Ͼ100 factors secreted from BMCs, 14 we do not infer that FGF9 "explains" the effects of cell therapy. Moreover, it has to be considered that our conditional transgenic and adenoviral approaches target the remote myocardium and border zone, whereas intracoronary cell transfer targets the border zone and infarcted area. Different therapeutic effects may therefore be observed in both situations (eg, hypertrophy of the remote myocardium has not been reported after BMC transfer). In any case, our data support the idea that secretome analyses of BMCs can lead to the identification of secreted factors with therapeutic activity after MI. 15, 16 
Conclusions
Conditional expression of FGF9 in the adult mouse myocardium enhances vascularization and hypertrophy, which, when superimposed on postinfarct remodeling, promotes functional benefits and reduces heart failure mortality. The beneficial effects of transgenic FGF9 can be reproduced by adenoviral FGF9 gene transfer, which should stimulate further research into the therapeutic potential of FGF9 after MI. 
CLINICAL PERSPECTIVE
Paracrine mechanisms are thought to contribute to the beneficial effects of bone marrow cells on perfusion and function of the infarcted heart that have been demonstrated in experimental studies and some clinical trials. We have previously identified fibroblast growth factor 9 (FGF9) as 1 of Ͼ100 paracrine factors that are secreted from bone marrow cells after myocardial infarction. In the embryonic heart, FGF9 is expressed by the epicardium and endocardium and provides an epithelial-to-mesenchymal signal to stimulate coronary artery formation and cardiomyoblast expansion in the developing myocardium. FGF9, however, is expressed only at very low levels in the adult heart. Using a tetracycline-responsive binary transgene system based on the ␣-myosin heavy chain promoter, we show here that conditional expression of FGF9 in the adult mouse myocardium supports functional adaptation and survival after myocardial infarction. Transgenic FGF9 stimulated left ventricular hypertrophy with microvessel expansion, reduced interstitial fibrosis, attenuated fetal gene expression, preserved diastolic but improved systolic function, and markedly reduced heart failure mortality. A single injection of an adenoviral vector encoding FGF9 promoted similar improvements in left ventricular systolic function and survival after myocardial infarction. Mechanistically, FGF9 acted primarily on endothelial cells to promote angiogenesis and paracrine release of prohypertrophic factors, including bone morphogenetic protein 6. These observations support the idea that secretome analyses in bone marrow cells can lead to the identification of secreted factors with therapeutic activity after myocardial infarction. Specifically, the data suggest a previously unrecognized therapeutic potential for FGF9 after myocardial infarction. 
Inducible cardiac-specific FGF9-transgenic mice and animal procedures
A tetracycline-responsive transgene system 3 was used to allow temporally-regulated expression of For an assessment of postinfarct survival, mice were followed and inspected daily from 24 h up to 6 weeks after surgery. Autopsies were performed on all dead animals, rupture was diagnosed by the presence of a blood clot around the heart and in the chest cavity, whereas heart failure was diagnosed by chest fluid accumulation. 5, 6 Six weeks after a sham operation, no deaths were observed in any of the genotypes. All animal procedures were approved by our local state authorities.
Adenoviral FGF9 gene transfer
Mouse FGF9 cDNA was cloned into a replication-deficient adenovirus using the AdEasy XL Vector System (Stratagene, La Jolla, CA). A replication-deficient adenovirus encoding β-galactosidase was used as control. Viruses were purified with the Adeno-X Virus Purification Kit (BD Biosciences, Franklin Lakes, NJ). Viruses were injected into the left ventricular (LV) cavity immediately after LAD ligation.
In vivo pressure-volume measurements
Left ventricular pressure-volume (P-V) loops were recorded with a 1.4 F micromanometer conductance catheter (SPR-839, Millar Instruments, Houston, TX) inserted via the right carotid 3 artery during isoflurane (2%) anesthesia. Steady-state P-V loops were sampled at a rate of 1 kHz and analyzed by a sample-blinded investigator (T.K.).
Echocardiography
Transthoracic echocardiography was performed with a linear 30 MHz transducer (VisualSonics, Toronto, Canada) in mice that were sedated with 1 to 1.5% isoflurane and placed on a heating pad to maintain body temperature. LV end-diastolic area (LVEDA) and end-systolic area (LVESA)
were recorded from the long-axis parasternal view. Fractional area change was calculated as
Histology
Left ventricles were fixed in phosphate-buffered 4% formaldehyde and embedded in paraffin.
Sections (5 µm in thickness) were cut from basal, midventricular, and apical LV slices and stained with Masson's trichrome which shows fibrosis in blue. To determine infarct size, scar length and total LV circumference were traced at the endocardial surface. Infarct sizes were calculated as the average ratio of scar length to total LV circumference in basal, midventricular, and apical sections.
Scar thickness was measured at the center of the infarct in the same sections and averaged. 
Quantitative PCR (qPCR)
Total RNA was extracted from LV myocardium by TRIzol (Invitrogen) and purified with RNeasy kits (Qiagen, Hilden, Germany). After reverse transcription (Superscript II, Invitrogen), qPCR was performed using the Brilliant SYBR Green Mastermix-Kit and the MX4000 multiplex QPCR System from Stratagene (PCR primers are shown in Supplemental Table 1 ).
Cell culture
Human coronary artery endothelial cells (HCAECs) were purchased from Provitro (Berlin, Germany) and grown in MCDB131 medium (Invitrogen) supplemented with 10% FCS. Cells from passage 3 to 7 were used. Mouse heart endothelial cells were isolated from 10-day old C57/BL6 mice as previously described. 7 In brief, ventricles were digested in collagenase I solution (265 U per heart) followed by magnetic cell sorting using Dynabeads (Invitrogen) coated with a rat anti-mouse CD31 monoclonal antibody (BD Biosciences ANP, atrial natriuretic peptide; MHC, myosin heavy chain; SERCA2a, sarco(endo)plasmic reticulum Ca 2+ ATPase-2a; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
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